Currently, investment opportunities in China's innovative drug sector are receiving more and more attention from international capital. According to the data, since the second half of the year, many innovative Chinese pharmaceutical companies, including BeiGene and Baili Tianheng, have welcomed intensive foreign research. Among the foreign-funded institutions surveyed, Point72 Asset Management Company, known as “Wall Street's craziest money-making machine,” has also appeared. At this point, many foreign-funded institutions believe that China's innovative pharmaceutical industry is facing multiple benefits, including improved R&D capabilities, policy support, overseas market expansion opportunities, and valuation attractiveness, and still has great potential for investment in the future. Since this year, the stock prices of many innovative pharmaceutical companies have risen markedly, and many individual stocks such as Shu Taishen, Rongchang Biotech, Onlikang, and Maiwei Biotech have risen by more than 100% during the year. At the same time, China's Innovative Pharmaceutical Company also welcomed intensive research from foreign-funded institutions. According to Wind data, since the second half of the year, BeiGene has been surveyed by 53 foreign-funded institutions. Foreign-funded institutions such as State Street Bank, BlackRock Fund, Paris Asset Management, Hanya Investment, and Value Partners appeared on BeiGene's August research list.

Currently, investment opportunities in China's innovative drug sector are receiving more and more attention from international capital. According to the data, since the second half of the year, many innovative Chinese pharmaceutical companies, including BeiGene and Baili Tianheng, have welcomed intensive foreign research. Among the foreign-funded institutions surveyed, Point72 Asset Management Company, known as “Wall Street's craziest money-making machine,” has also appeared. At this point, many foreign-funded institutions believe that China's innovative pharmaceutical industry is facing multiple benefits, including improved R&D capabilities, policy support, overseas market expansion opportunities, and valuation attractiveness, and still has great potential for investment in the future. Since this year, the stock prices of many innovative pharmaceutical companies have risen markedly, and many individual stocks such as Shu Taishen, Rongchang Biotech, Onlikang, and Maiwei Biotech have risen by more than 100% during the year. At the same time, China's Innovative Pharmaceutical Company also welcomed intensive research from foreign-funded institutions. According to Wind data, since the second half of the year, BeiGene has been surveyed by 53 foreign-funded institutions. Foreign-funded institutions such as State Street Bank, BlackRock Fund, Paris Asset Management, Hanya Investment, and Value Partners appeared on BeiGene's August research list.